Sequenom (SQNM) rises 4% after announcing "numerous leading healthcare providers" in the U.S. have begun ordering its MaterniT21 product, which is used to analyze a baby's DNA during pregnancy for signs of Down Syndrome. Ed Pullen believes the nature of Sequenom's product "raises huge questions" about its usage
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/